



IAP4 Rec'd PCT/PTO 22 DEC 2005

CT

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number 10/550,866

Filing Date September 23, 2005

First Named Inventor Drivas, D.

Art Unit

Examiner Name

Attorney Docket Number MP-02

ENCLOSURES (Check all that apply)

- ☐ Fee Transmittal Form
☐ Fee Attached
☐ Amendment/Reply
☐ After Final
☐ Affidavits/declaration(s)
☐ Extension of Time Request
☐ Express Abandonment Request
☒ Information Disclosure Statement

☐ Certified Copy of Priority Document(s)
☐ Reply to Missing Parts/
Incomplete Application
☐ Reply to Missing Parts
under 37 CFR 1.52 or 1.53

- ☐ Drawing(s)
☐ Licensing-related Papers
☐ Petition
☐ Petition to Convert to a
Provisional Application
☐ Power of Attorney, Revocation
Change of Correspondence Address
☐ Terminal Disclaimer
☐ Request for Refund
☐ CD, Number of CD(s) _____
☐ Landscape Table on CD

- ☐ After Allowance Communication to TC
☐ Appeal Communication to Board
of Appeals and Interferences
☐ Appeal Communication to TC
(Appeal Notice, Brief, Reply Brief)
☐ Proprietary Information
☐ Status Letter
☒ Other Enclosure(s) (please identify
below):
Form 1449
Fourteen (14) References
Return-receipt postcard

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Hoxie & Tso LLP		
Signature			
Printed name	Thomas Hoxie		
Date	December 19, 2005	Reg. No.	32,993

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Thomas Hoxie	Date	12/19/05

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

S/N 10/550,866



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Drivas, D.)	Examiner:
)	
Serial No.:	10/550,866)	Group Art Unit:
)	
Filed:	September 23, 2005)	Attorney Docket: MP-02
)	
Title:	Methods and Compositions for)	
	Treating and Preventing Eotaxin)	
	Mediated Inflammatory Conditions)	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


In accordance with 37 C.F.R. §1.97 *et. seq.*, Applicant provides the enclosed materials for the Examiner's consideration in connection with the above-identified patent application. Applicant respectfully requests that this Information Disclosure Statement and the documents listed on the attached Form 1449 and enclosed herewith be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

It is believed that no fee is necessary. If a fee is required, please charge the same to Deposit Account No. 50-3464.

The Examiner is invited to contact the Applicant's representative at the below-listed telephone number if there are any questions.

Respectfully submitted,

Date: December 19, 2005




Thomas Hoxie
Reg. No. 32,993


Thomas Hoxie
HOXIE & TSO LLP
374 Millburn Avenue
Suite 300E
Millburn, New Jersey 07041
973-467-2126
973-467-2128 (fax)

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in a box addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 19th day of December, 2005.

Thomas Hoxie



Signature

Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Complete if Known

Application Number	10/550,866
Filing Date	September 23, 2005
First Named Inventor	Dimitrios T. Drivas
Group Art Unit	
Examiner Name	

Sheet 1 of 1

Attorney Docket No: MP-02

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2005/0013799A1	1/2005	Skurkovich et al.	
	2005/0013800A1	1/2005	Skurkovich et al.	
	2003/0175290A1	9/2003	Renner et al.	
	6,403,782 B1	6/2002	Luster et al.	
	2002/0098523A1	7/2002	Vaughan et al.	
	6,093,405	7/2000	Zagury et al.	
	5,993,814	11/1999	Williams et al.	
	60/396,636		Bachmann et al.	
	60/331,045		Renner et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
	WO 04/096849 A2	11-11-2004	University of Manitoba and Manitoba Institute of Child Health		
	WO 03/082349 A1	10-09-2003	Mercia Pharma, LLC		
	WO 03/040164 A2	05-15-2003	Cytos Biotechnology AG		
	WO 02/056905 A2	07-25-2002	Cytos Biotechnology AG		
	WO 01/66754 A1	09-13-2001	Cambridge Antibody Technology Limited		
	WO 99/10534	03-04-1999	Center for Blood Research, Inc.		
	WO 95/07985	03-23-1995	National Heart & Lung Institute; Ludwig Institute for Cancer Research		

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/550,866
	Filing Date	September 23, 2005
	First Named Inventor	Dimitrios T. Drivas
	Group Art Unit	
	Examiner Name	
Sheet 2 of 2	Attorney Docket No: MP-02	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		JOSE, P.J., et al. <i>Eotaxin: Cloning of an Eosinophil Chemoattractant Cytokine and Increased mRNA Expression in Allergen-Challenged Guinea-Pig Lungs, Biochemical and Biophysical Research Communications</i> , November 1994, pages 788-794, Vol. 205, No. 1.	
		JOSE, P.J., et al. <i>Eotaxin: A Potent Eosinophil Chemoattractant Cytokine Detected in a Guinea Pig Model of Allergic Airways Inflammation</i> , <i>J. Exp. Med.</i> , March 1994, pages 881-887, Vol. 179.	
		GARCIA-ZEPEDA, E., et al. <i>Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia</i> , <i>Nature Medicine</i> , April 1996, pages 449-456, Vol. 2, No. 4.	
		HERTZ, M., et al. <i>Active Vaccination Against IL-5 Bypasses Immunological Tolerance and Ameliorates Experimental Asthma</i> , <i>Journal of Immunology</i> , October 2001, pages 3792-3799, Vol. 167, No. 7.	
		GUTIERREZ-RAMOS, J.C., et al. <i>Eotaxin: From an Eosinophilic Chemokine to a Major Regulator of Allergic Reactions</i> , <i>Immunology Today</i> , November 1999, pages 500-504, Vol. 20, No. 11.	
		PONATH, P.D., et al. <i>Cloning of the Human Eosinophil Chemoattractant, Eotaxin Expression, Receptor Binding, and Functional Suggest a Mechanism for the Selective Recruitment of Eosinophils</i> , <i>Journal of Clinical Investigation</i> , February 1996, pages 604-612, Vol. 97, No. 3.	
		TANNENBAUM, C.S., et al. <i>The CXC Chemokines IP-10 and Mig are Necessary for IL-12-Mediated Regression of the Mouse RENCA Tumor</i> , <i>Journal of Immunology</i> , July 1998, pages 927-932, Vol. 161, No. 2.	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached